With the emergence of increasingly potent androgen deprivation therapy, rates of treatment-emergent small-cell neuroendocrine prostate cancer are increasing. In a recent prospective study, Aggarwal and colleagues defined the frequency and clinical and genomic characteristics of these tumours.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nuhn, P. et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur. Urol. https://doi.org/10.1016/j.eururo.2018.03.028 (2018).
Davies, A. H., Beltran, H. & Zoubeidi, A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat. Rev. Urol. 15, 271–286 (2018).
Mosquera, J. M. et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15, 1–10 (2013).
di Sant’Agnese, P. A. Neuroendocrine differentiation in human prostatic carcinoma. Hum. Pathol. 23, 287–296 (1992).
Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492–2503 (2018).
Hu, C.-D., Choo, R. & Huang, J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front. Oncol. 5, 90 (2015).
Bluemn, E. G. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32, 474–489 (2017).
Jin, R. J. et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res. 64, 5489–5495 (2004).
Grabowska, M. M. et al. Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev. 33, 377–397 (2014).
Gupta, A. et al. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells. Prostate 68, 50–60 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Grabowska, M.M., Matusik, R.J. Therapy-induced small-cell disease: from mouse to man and back. Nat Rev Urol 15, 662–663 (2018). https://doi.org/10.1038/s41585-018-0084-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-018-0084-z
This article is cited by
-
A simple quantitative PCR assay to determine TRAMP transgene zygosity
Prostate Cancer and Prostatic Diseases (2021)